Pulmonary Hypertension – Pipeline Review, H2 2012
出 版 商：Global Markets Direct
出版日期：2012/08/31
頁 數：163頁
文件格式：PDF
價 格：
USD 2,000 (Single-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
Pulmonary Hypertension – Pipeline Review, H2 2012
Summary
Global Markets Direct’s, 'Pulmonary Hypertension - Pipeline Review, H2 2012', provides an overview of the Pulmonary Hypertension therapeutic pipeline. This report provides information on the therapeutic development for Pulmonary Hypertension, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Pulmonary Hypertension. 'Pulmonary Hypertension - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- A snapshot of the global therapeutic scenario for Pulmonary Hypertension.
- A review of the Pulmonary Hypertension products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Pulmonary Hypertension pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Pulmonary Hypertension.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Pulmonary Hypertension pipeline depth and focus of Pulmonary Hypertension therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Summary
Global Markets Direct’s, 'Pulmonary Hypertension - Pipeline Review, H2 2012', provides an overview of the Pulmonary Hypertension therapeutic pipeline. This report provides information on the therapeutic development for Pulmonary Hypertension, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Pulmonary Hypertension. 'Pulmonary Hypertension - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- A snapshot of the global therapeutic scenario for Pulmonary Hypertension.
- A review of the Pulmonary Hypertension products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Pulmonary Hypertension pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Pulmonary Hypertension.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Pulmonary Hypertension pipeline depth and focus of Pulmonary Hypertension therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Pulmonary Hypertension Overview 8
Therapeutics Development 9
An Overview of Pipeline Products for Pulmonary Hypertension 9
Pulmonary Hypertension Therapeutics under Development by Companies 11
Pulmonary Hypertension Therapeutics under Investigation by Universities/Institutes 14
Late Stage Products 16
Comparative Analysis 16
Mid Clinical Stage Products 17
Comparative Analysis 17
Early Clinical Stage Products 18
Comparative Analysis 18
Pre-Clinical Stage Products 19
Comparative Analysis 19
Pulmonary Hypertension Therapeutics – Products under Development by Companies 20
Pulmonary Hypertension Therapeutics – Products under Investigation by Universities/Institutes 23
Companies Involved in Pulmonary Hypertension Therapeutics Development 25
Bristol-Myers Squibb Company 25
Genzyme Corporation 26
Johnson & Johnson 27
Boehringer Ingelheim GmbH 28
Sanofi-Aventis 29
Gilead Sciences, Inc. 30
FibroGen, Inc. 31
Novartis AG 32
Actelion Ltd 33
InterMune, Inc. 34
Nippon Shinyaku Co., Ltd. 35
Pfizer Inc. 36
Celgene Corporation 37
Bayer AG 38
Geron Corporation 39
Oncothyreon Inc 40
Compugen Ltd. 41
LTT Bio-Pharma Co., Ltd. 42
axxonis Pharma AG 43
Auspex Pharmaceuticals 44
Promedior, Inc. 45
Mondobiotech Holding AG 46
Conatus Pharmaceuticals Inc. 47
GenKyoTex S.A. 48
Stromedix, Inc. 49
ImmuneRegen BioSciences, Inc. 50
ImmuneWorks, LLC 51
Pacific Therapeutics Ltd. 52
Pulmonary Hypertension – Therapeutics Assessment 53
Assessment by Monotherapy Products 53
Assessment by Combination Products 54
Assessment by Route of Administration 55
Assessment by Molecule Type 58
Drug Profiles 61
BAY 63-2521 - Drug Profile 61
BAY 63-2521 - Drug Profile 63
GC1008 - Drug Profile 65
JNK CC-930 - Drug Profile 66
Esbriet - Drug Profile 67
NBT-485 - Drug Profile 69
FG-3019 - Drug Profile 70
Macitentan - Drug Profile 72
Homspera - Drug Profile 74
PC-SOD - Drug Profile 76
CGEN-25009 - Drug Profile 78
PX-866 - Drug Profile 79
Vargatef - Drug Profile 80
PRM-151 - Drug Profile 82
STX-100 - Drug Profile 84
Selexipag - Drug Profile 85
QAX-576 - Drug Profile 87
DHEA - Drug Profile 89
IW001 - Drug Profile 90
Prednisone + Azathioprine + N-Acetylcysteine - Drug Profile 92
Sildenafil - Drug Profile 93
GKT137831 - Drug Profile 94
CNTO 888 - Drug Profile 95
PTL-202 - Drug Profile 97
Sildenafil Citrate - Drug Profile 98
Emricasan - Drug Profile 99
GRN510 - Drug Profile 101
Interferon Gamma - Drug Profile 102
Viagra + Cozaar - Drug Profile 103
Tracleer - Drug Profile 104
GS 6624 - Drug Profile 106
BMS-986202 - Drug Profile 108
Anakinra - Drug Profile 109
Tadalafil - Drug Profile 111
Gleevec - Drug Profile 112
Avastin + Gleevec - Drug Profile 113
Carbon Monoxide - Drug Profile 114
Salbutamol Sulphate - Drug Profile 115
L-Arginine - Drug Profile 116
Sodium Nitroprusside - Drug Profile 117
Bosentan - Drug Profile 118
DasKloster 0247-01 - Drug Profile 119
Inhaled rhPTX-2 - Drug Profile 120
Plasma Exchange + Rituximab + Corticosteroids - Drug Profile 121
SAR156597 - Drug Profile 122
Tadalafil - Drug Profile 123
Sodium Nitrite - Drug Profile 124
DasKloster 1000-03 - Drug Profile 125
DasKloster 1001-01 - Drug Profile 126
DasKloster 0247–01 - Drug Profile 127
nitric oxide - Drug Profile 128
Pulmonary Hypertension Therapeutics – Drug Profile Updates 130
Pulmonary Hypertension Therapeutics – Discontinued Products 147
Pulmonary Hypertension Therapeutics - Dormant Products 148
Pulmonary Hypertension – Product Development Milestones 151
Featured News & Press Releases 151
Appendix 158
Methodology 158
Coverage 158
Secondary Research 158
Primary Research 158
Expert Panel Validation 158
Contact Us 159
Disclaimer 159
List of Tables
Number of Products Under Development for Pulmonary Hypertension, H2 2012 13
Products under Development for Pulmonary Hypertension – Comparative Analysis, H2 2012 14
Number of Products under Development by Companies, H2 2012 16
Number of Products under Development by Companies, H2 2012 (Contd..1) 17
Number of Products under Investigation by Universities/Institutes, H2 2012 19
Comparative Analysis by Late Stage Development, H2 2012 20
Comparative Analysis by Mid Clinical Stage Development, H2 2012 21
Comparative Analysis by Early Clinical Stage Development, H2 2012 22
Comparative Analysis by Pre-Clinical Stage Development, H2 2012 23
Products under Development by Companies, H2 2012 24
Products under Development by Companies, H2 2012 (Contd..1) 25
Products under Development by Companies, H2 2012 (Contd..2) 26
Products under Investigation by Universities/Institutes, H2 2012 27
Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 28
Bristol-Myers Squibb Company, H2 2012 29
Genzyme Corporation, H2 2012 30
Johnson & Johnson, H2 2012 31
Boehringer Ingelheim GmbH, H2 2012 32
Sanofi-Aventis, H2 2012 33
Gilead Sciences, Inc., H2 2012 34
FibroGen, Inc., H2 2012 35
Novartis AG, H2 2012 36
Actelion Ltd, H2 2012 37
InterMune, Inc., H2 2012 38
Nippon Shinyaku Co., Ltd., H2 2012 39
Pfizer Inc., H2 2012 40
Celgene Corporation, H2 2012 41
Bayer AG, H2 2012 42
Geron Corporation, H2 2012 43
Oncothyreon Inc, H2 2012 44
Compugen Ltd., H2 2012 45
LTT Bio-Pharma Co., Ltd., H2 2012 46
axxonis Pharma AG, H2 2012 47
Auspex Pharmaceuticals, H2 2012 48
Promedior, Inc., H2 2012 49
Mondobiotech Holding AG, H2 2012 50
Conatus Pharmaceuticals Inc., H2 2012 51
GenKyoTex S.A., H2 2012 52
Stromedix, Inc., H2 2012 53
ImmuneRegen BioSciences, Inc., H2 2012 54
ImmuneWorks, LLC, H2 2012 55
Pacific Therapeutics Ltd., H2 2012 56
Assessment by Monotherapy Products, H2 2012 57
Assessment by Combination Products, H2 2012 58
Assessment by Stage and Route of Administration, H2 2012 61
Assessment by Stage and Molecule Type, H2 2012 64
Pulmonary Hypertension Therapeutics – Drug Profile Updates 134
Pulmonary Hypertension Therapeutics – Discontinued Products 151
Pulmonary Hypertension Therapeutics – Dormant Products 152
Pulmonary Hypertension Therapeutics – Dormant Products (Contd..1) 153
Pulmonary Hypertension Therapeutics – Dormant Products (Contd..2) 154
List of Figures
Number of Products under Development for Pulmonary Hypertension, H2 2012 13
Products under Development for Pulmonary Hypertension – Comparative Analysis, H2 2012 14
Products under Development by Companies, H2 2012 15
Products under Investigation by Universities/Institutes, H2 2012 18
Late Stage Products, H2 2012 20
Mid Clinical Stage Products, H2 2012 21
Early Clinical Stage Products, H2 2012 22
Pre-Clinical Stage Products, H2 2012 23
Assessment by Monotherapy Products, H2 2012 57
Assessment by Combination Products, H2 2012 58
Assessment by Route of Administration, H2 2012 59
Assessment by Stage and Route of Administration, H2 2012 60
Assessment by Molecule Type, H2 2012 62
Assessment by Stage and Molecule Type, H2 2012 63
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Pulmonary Hypertension Overview 8
Therapeutics Development 9
An Overview of Pipeline Products for Pulmonary Hypertension 9
Pulmonary Hypertension Therapeutics under Development by Companies 11
Pulmonary Hypertension Therapeutics under Investigation by Universities/Institutes 14
Late Stage Products 16
Comparative Analysis 16
Mid Clinical Stage Products 17
Comparative Analysis 17
Early Clinical Stage Products 18
Comparative Analysis 18
Pre-Clinical Stage Products 19
Comparative Analysis 19
Pulmonary Hypertension Therapeutics – Products under Development by Companies 20
Pulmonary Hypertension Therapeutics – Products under Investigation by Universities/Institutes 23
Companies Involved in Pulmonary Hypertension Therapeutics Development 25
Bristol-Myers Squibb Company 25
Genzyme Corporation 26
Johnson & Johnson 27
Boehringer Ingelheim GmbH 28
Sanofi-Aventis 29
Gilead Sciences, Inc. 30
FibroGen, Inc. 31
Novartis AG 32
Actelion Ltd 33
InterMune, Inc. 34
Nippon Shinyaku Co., Ltd. 35
Pfizer Inc. 36
Celgene Corporation 37
Bayer AG 38
Geron Corporation 39
Oncothyreon Inc 40
Compugen Ltd. 41
LTT Bio-Pharma Co., Ltd. 42
axxonis Pharma AG 43
Auspex Pharmaceuticals 44
Promedior, Inc. 45
Mondobiotech Holding AG 46
Conatus Pharmaceuticals Inc. 47
GenKyoTex S.A. 48
Stromedix, Inc. 49
ImmuneRegen BioSciences, Inc. 50
ImmuneWorks, LLC 51
Pacific Therapeutics Ltd. 52
Pulmonary Hypertension – Therapeutics Assessment 53
Assessment by Monotherapy Products 53
Assessment by Combination Products 54
Assessment by Route of Administration 55
Assessment by Molecule Type 58
Drug Profiles 61
BAY 63-2521 - Drug Profile 61
BAY 63-2521 - Drug Profile 63
GC1008 - Drug Profile 65
JNK CC-930 - Drug Profile 66
Esbriet - Drug Profile 67
NBT-485 - Drug Profile 69
FG-3019 - Drug Profile 70
Macitentan - Drug Profile 72
Homspera - Drug Profile 74
PC-SOD - Drug Profile 76
CGEN-25009 - Drug Profile 78
PX-866 - Drug Profile 79
Vargatef - Drug Profile 80
PRM-151 - Drug Profile 82
STX-100 - Drug Profile 84
Selexipag - Drug Profile 85
QAX-576 - Drug Profile 87
DHEA - Drug Profile 89
IW001 - Drug Profile 90
Prednisone + Azathioprine + N-Acetylcysteine - Drug Profile 92
Sildenafil - Drug Profile 93
GKT137831 - Drug Profile 94
CNTO 888 - Drug Profile 95
PTL-202 - Drug Profile 97
Sildenafil Citrate - Drug Profile 98
Emricasan - Drug Profile 99
GRN510 - Drug Profile 101
Interferon Gamma - Drug Profile 102
Viagra + Cozaar - Drug Profile 103
Tracleer - Drug Profile 104
GS 6624 - Drug Profile 106
BMS-986202 - Drug Profile 108
Anakinra - Drug Profile 109
Tadalafil - Drug Profile 111
Gleevec - Drug Profile 112
Avastin + Gleevec - Drug Profile 113
Carbon Monoxide - Drug Profile 114
Salbutamol Sulphate - Drug Profile 115
L-Arginine - Drug Profile 116
Sodium Nitroprusside - Drug Profile 117
Bosentan - Drug Profile 118
DasKloster 0247-01 - Drug Profile 119
Inhaled rhPTX-2 - Drug Profile 120
Plasma Exchange + Rituximab + Corticosteroids - Drug Profile 121
SAR156597 - Drug Profile 122
Tadalafil - Drug Profile 123
Sodium Nitrite - Drug Profile 124
DasKloster 1000-03 - Drug Profile 125
DasKloster 1001-01 - Drug Profile 126
DasKloster 0247–01 - Drug Profile 127
nitric oxide - Drug Profile 128
Pulmonary Hypertension Therapeutics – Drug Profile Updates 130
Pulmonary Hypertension Therapeutics – Discontinued Products 147
Pulmonary Hypertension Therapeutics - Dormant Products 148
Pulmonary Hypertension – Product Development Milestones 151
Featured News & Press Releases 151
Appendix 158
Methodology 158
Coverage 158
Secondary Research 158
Primary Research 158
Expert Panel Validation 158
Contact Us 159
Disclaimer 159
List of Tables
Number of Products Under Development for Pulmonary Hypertension, H2 2012 13
Products under Development for Pulmonary Hypertension – Comparative Analysis, H2 2012 14
Number of Products under Development by Companies, H2 2012 16
Number of Products under Development by Companies, H2 2012 (Contd..1) 17
Number of Products under Investigation by Universities/Institutes, H2 2012 19
Comparative Analysis by Late Stage Development, H2 2012 20
Comparative Analysis by Mid Clinical Stage Development, H2 2012 21
Comparative Analysis by Early Clinical Stage Development, H2 2012 22
Comparative Analysis by Pre-Clinical Stage Development, H2 2012 23
Products under Development by Companies, H2 2012 24
Products under Development by Companies, H2 2012 (Contd..1) 25
Products under Development by Companies, H2 2012 (Contd..2) 26
Products under Investigation by Universities/Institutes, H2 2012 27
Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 28
Bristol-Myers Squibb Company, H2 2012 29
Genzyme Corporation, H2 2012 30
Johnson & Johnson, H2 2012 31
Boehringer Ingelheim GmbH, H2 2012 32
Sanofi-Aventis, H2 2012 33
Gilead Sciences, Inc., H2 2012 34
FibroGen, Inc., H2 2012 35
Novartis AG, H2 2012 36
Actelion Ltd, H2 2012 37
InterMune, Inc., H2 2012 38
Nippon Shinyaku Co., Ltd., H2 2012 39
Pfizer Inc., H2 2012 40
Celgene Corporation, H2 2012 41
Bayer AG, H2 2012 42
Geron Corporation, H2 2012 43
Oncothyreon Inc, H2 2012 44
Compugen Ltd., H2 2012 45
LTT Bio-Pharma Co., Ltd., H2 2012 46
axxonis Pharma AG, H2 2012 47
Auspex Pharmaceuticals, H2 2012 48
Promedior, Inc., H2 2012 49
Mondobiotech Holding AG, H2 2012 50
Conatus Pharmaceuticals Inc., H2 2012 51
GenKyoTex S.A., H2 2012 52
Stromedix, Inc., H2 2012 53
ImmuneRegen BioSciences, Inc., H2 2012 54
ImmuneWorks, LLC, H2 2012 55
Pacific Therapeutics Ltd., H2 2012 56
Assessment by Monotherapy Products, H2 2012 57
Assessment by Combination Products, H2 2012 58
Assessment by Stage and Route of Administration, H2 2012 61
Assessment by Stage and Molecule Type, H2 2012 64
Pulmonary Hypertension Therapeutics – Drug Profile Updates 134
Pulmonary Hypertension Therapeutics – Discontinued Products 151
Pulmonary Hypertension Therapeutics – Dormant Products 152
Pulmonary Hypertension Therapeutics – Dormant Products (Contd..1) 153
Pulmonary Hypertension Therapeutics – Dormant Products (Contd..2) 154
List of Figures
Number of Products under Development for Pulmonary Hypertension, H2 2012 13
Products under Development for Pulmonary Hypertension – Comparative Analysis, H2 2012 14
Products under Development by Companies, H2 2012 15
Products under Investigation by Universities/Institutes, H2 2012 18
Late Stage Products, H2 2012 20
Mid Clinical Stage Products, H2 2012 21
Early Clinical Stage Products, H2 2012 22
Pre-Clinical Stage Products, H2 2012 23
Assessment by Monotherapy Products, H2 2012 57
Assessment by Combination Products, H2 2012 58
Assessment by Route of Administration, H2 2012 59
Assessment by Stage and Route of Administration, H2 2012 60
Assessment by Molecule Type, H2 2012 62
Assessment by Stage and Molecule Type, H2 2012 63
